Viridian Therapeutics (NASDAQ: VRDN) has announced positive top-line results from its Phase III THRIVE study evaluating VRDN-001 (veligrotug) in patients with thyroid eye disease (TED). The study's findings, which align with expectations, indicate a favorable efficacy and safety profile for veligrotug, potentially positioning it as a competitor to Tepezza in the TED market.
THRIVE Study Results
The Phase III THRIVE study met its primary and secondary endpoints, demonstrating that veligrotug could be an approvable medication for TED. While some outcomes slightly exceeded base case predictions, others were marginally below, the overall results support veligrotug's potential to capture a moderate portion of Tepezza's market share.
Market Potential and Financial Outlook
Analysts estimate that veligrotug could achieve annual sales between $500 million and $700 million, assuming a 25-35% market penetration of Tepezza's share. B.Riley has raised its price target for Viridian to $22.00, reflecting a revised probability of success for the drug, taking into account the recent study outcomes and the company's concurrent equity offering.
Viridian's financial stability is bolstered by a strong cash position, with $571.4 million in cash and equivalents as of June 30, 2024. The company recently initiated a public offering of $150 million of its common stock and Series B non-voting convertible preferred stock to fund clinical development programs, working capital, and general corporate purposes.
Ongoing Clinical Development
Viridian is actively advancing its TED treatment pipeline, with ongoing Phase 3 trials for VRDN-001 and VRDN-003. The company has completed enrollment for its Phase 3 trial of VRDN-001, with top-line results expected in September 2024. Additionally, Viridian has initiated two global phase 3 trials, REVEAL-1 and REVEAL-2, for VRDN-003, a subcutaneous form of the antibody.
Analyst Confidence
Analyst firms, including Goldman Sachs, RBC Capital, and Wolfe Research, project potential revenue from VRDN-001 to reach approximately $690 million worldwide by 2027. Analysts from Stifel and BTIG have also increased their price targets for Viridian Therapeutics, reflecting confidence in the company's ongoing trials and the potential of its TED treatments.
